The observation, however, that PBA administration, but not LCN2 deficiency, decreased the severity of interstitial fibrosis in WT1+/mut mutant mice suggests that PBA might act by modulating additional actors of CKD progression. The gene discussed is LCN2; the disease is chronic kidney disease.